GMAB

Business Context and Reporting Period

Company: Genmab A/S (Genmab)
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended December 31, 2023
Accounting Standards: International Financial Reporting Standards (IFRS)
Reporting Currency: Danish Kroner (DKK)

Genmab is an international biotechnology company focused on developing antibody-based products for cancer and other serious diseases. The company operates a hybrid business model, retaining rights to proprietary products (e.g., Tivdak, EPKINLY) while licensing technology and products to partners (e.g., Janssen, AbbVie, Pfizer) for royalties and milestones. As of December 31, 2023, the company employed 2,204 people.

Key Financial Metrics

Note: The provided text incorporates financial review data by reference and does not contain specific numerical values for revenue, profit, cash flow, or margins for the 2023 period. The following qualitative metrics are derived from the text.

• Revenue Composition: Revenue is derived from royalties, milestone payments, collaboration revenue, license fees, and net product sales. In 2023, royalties and milestone payments from Janssen related to DARZALEX accounted for 68% of total revenue.
• Product Sales: Net product sales are currently derived solely from EPKINLY (epcoritamab), for which Genmab is the principal in the U.S. and Japan. Tivdak (tisotumab vedotin) sales in the U.S. are recorded by Pfizer, with Genmab receiving a 50% profit share.
• Operating Expenses: Research and development (R&D) expenses represent the majority of operating expenses. Selling, general, and administrative (SG&A) expenses are increasing due to the expansion of commercialization capabilities for Tivdak and EPKINLY.
• Capitalization: As of the close of the period, there were 66,074,535 Ordinary Shares and 47,714,390 American Depositary Shares (ADS) outstanding.
• Debt and Liquidity: The text does not provide specific debt or liquidity figures, stating that these are incorporated by reference from the Annual Report 2023.

Material Changes and Operational Highlights

• Commercialization Expansion: Genmab transitioned to a commercial-stage company with the launch of Tivdak and EPKINLY. In 2023, the company began co-commercializing EPKINLY with AbbVie in the U.S. and Japan.
• Regulatory Milestones:
  • EPKINLY: Received accelerated FDA approval (May 2023) and conditional marketing authorization in Europe and approval in Japan (September 2023) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
  • Tivdak: The Phase III innovaTV 301 confirmatory trial met its primary endpoint of overall survival in September 2023, supporting the conversion of accelerated approval to full approval.
  • Partnered Products: Janssen received FDA approval for TALVEY (talquetamab) in August 2023. Janssen also submitted multiple supplemental BLAs for RYBREVANT (amivantamab) for expanded indications in non-small cell lung cancer (NSCLC).
• Portfolio Adjustments: In September 2023, Genmab discontinued the DuoHexaBody-CD37 program following a strategic evaluation. This decision was not based on safety or regulatory concerns.
• Employee Growth: The workforce grew from 548 employees in 2019 to 2,204 at the end of 2023.

Guidance, Risks, and Contingencies

Material Weakness in Internal Controls

Management identified a material weakness in internal control over financial reporting as of December 31, 2023. The deficiency relates to the recording of royalty revenue, specifically the inadequate assessment of accounting for royalty reduction provisions in commercial agreements. While this did not cause a material misstatement in the 2023 financial statements, it resulted in immaterial errors in prior periods (2021 and 2022), which have been revised. Remediation efforts are underway.

Key Risks and Contingencies

• Dependence on Janssen/DARZALEX: Financial results are substantially dependent on the commercial success of DARZALEX. Royalties are time-limited and subject to reduction upon patent expiration or biosimilar entry. Patents do not begin to expire until March 2026.
• Commercialization Risks: Genmab has limited experience commercializing products. The success of Tivdak and EPKINLY depends on market acceptance, reimbursement, and the ability to build commercial infrastructure.
• Legal Proceedings: Genmab was engaged in arbitration with Janssen regarding royalty provisions. The first arbitration (April 2022) denied Genmab's claims. A second arbitration (April 2023) was dismissed on procedural grounds, a decision affirmed on January 23, 2024.
• Regulatory and Pricing: Risks include the Inflation Reduction Act (IRA) in the U.S., which allows Medicare price negotiation starting in 2026, and potential pricing pressures globally.
• Foreign Exchange: The company is exposed to currency risk as it reports in DKK but receives significant revenue in USD and EUR.

Investor Verification Checklist

• Financial Statements: Verify specific revenue, net income, and cash flow figures in the Audited Financial Statements (incorporated by reference in Exhibit 99.1(a) of Form 6-K), as they are not detailed in this text.
• Internal Control Remediation: Monitor the progress of remediation for the material weakness regarding royalty revenue accounting to ensure future financial reporting accuracy.
• DARZALEX Royalty Timeline: Confirm the specific patent expiration dates and biosimilar entry risks for DARZALEX in key markets to assess the duration of the primary revenue stream.
• EPKINLY and Tivdak Sales: Track the commercial performance and reimbursement status of EPKINLY and Tivdak, as these are critical for diversifying revenue away from Janssen royalties.
• Confirmatory Trial Outcomes: Verify the regulatory acceptance of the innovaTV 301 trial results for Tivdak to confirm the transition from accelerated to full approval.